Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax.
Moritz FürstenauJonathan WeissAdam GizaFabian FranzenSandra RobrechtAnna-Maria FinkKirsten FischerChristof SchneiderEugen TauschStephan StilgenbauerMatthias RitgenAnke SchilhabelMonika BrüggemannBarbara EichhorstMichael HallekPaula CramerPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
On the basis of these findings, ctDNA-based MRD assessment appears to be a promising method to complement cell-based MRD approaches like flow cytometry that focus on circulating CLL cells in the peripheral blood.